AQR Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $103M | Buy |
5,976,414
+1,898,995
| +47% | +$32.9M | 0.09% | 329 |
|
|
2025
Q1 | $89.2M | Buy |
4,077,419
+2,220,977
| +120% | +$48.6M | 0.09% | 299 |
|
|
2024
Q4 | $59.2M | Buy |
1,856,442
+1,039,182
| +127% | +$33.2M | 0.08% | 334 |
|
|
2024
Q3 | $23.6M | Buy |
817,260
+570,380
| +231% | +$16.4M | 0.03% | 597 |
|
|
2024
Q2 | $9.18M | Buy |
246,880
+190,420
| +337% | +$7.08M | 0.01% | 781 |
|
|
2024
Q1 | $3.26M | Buy |
+56,460
| New | +$3.26M | 0.01% | 1192 |
|
|
2023
Q3 | – | Sell |
-10,926
| Closed | -$995K | – | 2313 |
|
|
2023
Q2 | $995K | Sell |
10,926
-4,263
| -28% | -$388K | ﹤0.01% | 1553 |
|
|
2023
Q1 | $1M | Sell |
15,189
-2,002
| -12% | -$132K | ﹤0.01% | 1549 |
|
|
2022
Q4 | $889K | Buy |
17,191
+8,792
| +105% | +$455K | ﹤0.01% | 1605 |
|
|
2022
Q3 | $574K | Buy |
8,399
+92
| +1% | +$6.29K | ﹤0.01% | 1726 |
|
|
2022
Q2 | $376K | Buy |
+8,307
| New | +$376K | ﹤0.01% | 1779 |
|
|
2021
Q4 | – | Sell |
-40,966
| Closed | -$1.35M | – | 2196 |
|
|
2021
Q3 | $1.35M | Buy |
40,966
+36,478
| +813% | +$1.2M | ﹤0.01% | 1382 |
|
|
2021
Q2 | $284K | Buy |
+4,488
| New | +$284K | ﹤0.01% | 2057 |
|
|
2021
Q1 | – | Sell |
-3,941
| Closed | -$225K | – | 2188 |
|
|
2020
Q4 | $225K | Sell |
3,941
-11,928
| -75% | -$681K | ﹤0.01% | 2055 |
|
|
2020
Q3 | $479K | Sell |
15,869
-11,044
| -41% | -$333K | ﹤0.01% | 1745 |
|
|
2020
Q2 | $879K | Sell |
26,913
-7,298
| -21% | -$238K | ﹤0.01% | 1507 |
|
|
2020
Q1 | $917K | Buy |
34,211
+13,591
| +66% | +$364K | ﹤0.01% | 1367 |
|
|
2019
Q4 | $631K | Buy |
+20,620
| New | +$631K | ﹤0.01% | 1673 |
|